11-Dec-2025
Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating
TipRanks (Thu, 11-Dec 8:05 PM ET)
CDC study finds COVID shot significantly reduced ER visits for children
Seeking Alpha News (Thu, 11-Dec 5:37 PM ET)
Moderna on track to extend gains for the seventh straight trading day
Seeking Alpha News (Thu, 11-Dec 4:03 PM ET)
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Benzinga (Thu, 11-Dec 1:39 PM ET)
Most shorted S&P 500 stocks in November
Seeking Alpha News (Thu, 11-Dec 9:35 AM ET)
Seeking Alpha News (Thu, 11-Dec 7:11 AM ET)
FDA expands COVID-19 shot safety probe to include adults - report
Seeking Alpha News (Tue, 9-Dec 5:34 PM ET)
Global AI Infrastructure Shift Ignites Biotech Growth Phase
Globe Newswire (Tue, 9-Dec 9:25 AM ET)
Moderna’s Growth Prospects: Balancing Revenue Potential and Legal Challenges
TipRanks (Tue, 9-Dec 7:15 AM ET)
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, and Bristol Myers in focus
Seeking Alpha News (Sun, 7-Dec 9:05 AM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of December 11, 2025, MRNA stock price climbed to $29.63 with 7,278,472 million shares trading.
MRNA has a beta of 1.51, meaning it tends to be more sensitive to market movements. MRNA has a correlation of 0.16 to the broad based SPY ETF.
MRNA has a market cap of $11.57 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $1 billion in Revenue and -$.51 earnings per share. This beat revenue expectation by $150 million and exceeded earnings estimates by $1.66.
In the last 3 years, MRNA traded as high as $217.25 and as low as $22.28.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, VB, RSP, XBI.
MRNA has underperformed the market in the last year with a return of -28.6%, while SPY returned +15.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRNA shares. However, MRNA has outperformed the market in the last 3 month and 2 week periods, returning +21.9% and +18.5%, while SPY returned +5.9% and +1.4%, respectively. This indicates MRNA has been having a stronger performance recently.
MRNA support price is $27.83 and resistance is $30.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.